HET0016 

HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC₅₀ values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth^[1][2].

HET0016 is a selective, non-competitive and irreversible inhibitor of CYP4A ^[1].
HET0016 (100 μM; 24 hours, 48 hours) decreases migration and invasion of breast cancer metastatic cells ^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

HET0016 (10 mg/kg/day; i.v.; for 3 weeks) reduces tumor volume and lung metastasis in an immunocompetent breast cancer mouse model^[2].
HET0016 reduces the metalloproteinases’ levels in the lungs via PI3K/AKT pathway in mice^[2].
HET0016 decreases expression of pro-inflammatory and growth factors and granulocytic MDSCs population in lung microenvironment^[2].
HET0016 protects BBB dysfunction after I/R by regulating the expression of MMP-9 and tight junction proteins^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

206.28

Solid

C₁₂H₁₈N₂O

339068-25-6

CCCCC1=CC=C(C(C)=C1)/N=C/NO

Room temperature in continental US; may vary elsewhere.

• [1]. Seki T, et al. Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull. 2005 Sep;28(9):1651-4.  [Content Brief]

  [2]. Borin TF, et al. HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model. PLoS One. 2017 Jun 13;12(6):e0178830.  [Content Brief]

  [3]. Liu Y, et al. The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res. 2014 Jan 28;1544:45-53.  [Content Brief]